Trial Profile
A Phase II Study of Lorlatnib in ROS1 Rearranged Advanced NSCLC
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Lorlatinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Sep 2020 Status changed from not yet recruiting to recruiting.
- 20 Mar 2019 Planned initiation date changed from 1 Dec 2018 to 27 Mar 2019.
- 08 Aug 2018 New trial record